文献速递消化系统肿瘤骨软组织肉瘤与黑色素瘤

胚系BRCA相关胰腺癌对铂类和PARP抑制剂应答谱的临床与临床前研究

Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
PubMed 文献 · Cancer Discov · 2023-01-01

该研究基于125例胚系BRCA相关胰腺导管腺癌(glBRCA PDAC)患者,按对铂类/PARP抑制剂的应答谱分层:难治(OS<6个月)、持久应答后获得性耐药(OS<36个月)和长期应答者(OS>36个月)。从25例患者不同临床时间点建立人源肿瘤异种移植模型(PDX),体内及离体培养(EVOC)的药敏与临床应答相关。同源重组功能正常和恢复部分功能的二次突变是最主要耐药机制,但部分同源重组缺陷(HRD)患者仍出现临床耐药,其肿瘤呈基底样分子亚型且非整倍体程度更高。

要点

  • glBRCA PDAC对铂类/PARP抑制剂应答良好,但多数患者最终出现耐药。
  • 同源重组功能正常及二次突变恢复部分功能是主要耐药机制。
  • 部分HRD患者仍临床耐药,肿瘤呈基底样亚型且非整倍体更高。

核心结论

  • glBRCA PDAC对铂类/PARP抑制剂应答良好,但多数患者出现耐药,该独特亚群需要更多治疗选择。
  • 临床前模型(含EVOC)可预测glBRCA PDAC对治疗的应答,有望为时间敏感的医疗决策提供信息。

研究设计与样本

  • 研究纳入125例glBRCA PDAC患者,按对铂类/PARP抑制剂的应答谱分为难治(OS<6个月)、持久应答后获得性耐药(OS<36个月)和长期应答者(OS>36个月)。
  • 从25例glBRCA PDAC患者不同临床时间点建立PDX模型,并进行体内及离体培养(EVOC)药敏检测。

主要发现

  • 体内及EVOC对铂类/PARP抑制剂的应答与临床应答相关。
  • 同源重组功能正常和二次突变恢复部分功能是最主要的耐药机制。
  • 部分HRD患者出现临床耐药,其肿瘤呈基底样分子亚型且非整倍体程度更高。
  • HRD PDAC肿瘤突变负荷高,伴有二次突变的肿瘤突变负荷显著更高。
  • 在新型人源化glBRCA PDAC PDX模型中,抗PD-1治疗减缓肿瘤生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS) <6 months], (ii) durable response followed by acquired resistance (OS <36 months), and (iii) long-term responders (OS >36 months). Patient-derived xenografts (PDX) were generated from 25 patients with glBRCA PDAC at different clinical time points. Response to platinum/PARP inhibition in vivo and ex vivo culture (EVOC) correlated with clinical response. We deciphered the mechanisms of resistance in glBRCA PDAC and identified homologous recombination (HR) proficiency and secondary mutations restoring partial functionality as the most dominant resistant mechanism. Yet, a subset of HR-deficient (HRD) patients demonstrated clinical resistance. Their tumors displayed basal-like molecular subtype and were more aneuploid. Tumor mutational burden was high in HRD PDAC and significantly higher in tumors with secondary mutations. Anti-PD-1 attenuated tumor growth in a novel humanized glBRCA PDAC PDX model. This work demonstrates the utility of preclinical models, including EVOC, to predict the response of glBRCA PDAC to treatment, which has the potential to inform time-sensitive medical decisions. SIGNIFICANCE: glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development. This article is highlighted in the In This Issue feature, p. 1749.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Stossel C, Raitses-Gurevich M, Atias D, et al. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting. Cancer Discov. 2023. PMID: 37449843. doi:10.1158/2159-8290.CD-22-0412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。